# SABR-COMET-3 (NCT03862911)

> Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: oligometastatic cancer (1-3 metastases)

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03862911
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: British Columbia Cancer Agency
- Conditions: Metastatic Tumors
- Interventions: palliative radiotherapy; Stereotactic ablative radiotherapy
- Enrollment: 330
- Primary outcome: Overall survival

## Indexed commentary on SABR-COMET-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 22 posts on X
- 3 YouTube videos
- 3 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=sabr-comet-3-nct03862911

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03862911", "email": "<work email>"}; the inbox owner confirms by the emailed link.